Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 63 of 5804
-
New combo therapy aims to extend life in tough pancreatic cancer
Disease control Recruiting nowTo evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer
Phase: PHASE2, PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?
Disease control OngoingThis study is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable locally advanced or metastatic HER2-positive breast cancer who had failed previous treatment with taxanes and trastuzumab.
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for kids with tough lymphoma: global trial launches
Disease control Recruiting nowThe Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL). B-NHL is a type of cancer that develops inside or outside of lymph …
Phase: PHASE2, PHASE3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a new drug shield hearts and kidneys in overweight people?
Disease control OngoingThe main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardi…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Gene-Editing shot could slash cholesterol for good
Disease control Recruiting nowVT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-1…
Phase: PHASE1 • Sponsor: Verve Therapeutics, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug cocktail aims to wipe out HER2 breast cancer before surgery
Disease control Recruiting nowThis is a single-arm, multicenter clinical study designed to evaluate the efficacy and safety of pyrotinib and trastuzumab combined with pegylated liposomal doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel for injection albumin bound as neoadjuvant therapy in…
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo aims to outsmart lung cancer resistance
Disease control Recruiting nowThe purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R)…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug aims to slash fractures in kids with brittle bones
Disease control OngoingThe primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any fractures at 12-months and change in lumbar spine bone mineral density (BMD) Z-…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take on tough childhood cancers
Disease control Recruiting nowThe main purpose of this study is to evaluate the safety, to establish the recommended dose, and to evaluate the antitumor effect of CD7-CART01 in pediatric patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LL).
Phase: PHASE1, PHASE2 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Hope for kids with rare cancer: new combo therapy shows promise
Disease control Recruiting nowThis phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neurob…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Gene-Editing breakthrough aims to fix immune cells in rare disease
Disease control Recruiting nowBackground: Chronic granulomatous disease (CGD) is a rare immune disorder caused by a mutation in the CYBB gene. People with CGD have white blood cells that do not work properly and are at greater risk of getting infections. Gene therapy using lentivector has helped people with …
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Double punch for lymphoma: stem cell transplant plus CAR-T therapy
Disease control Recruiting nowClinical trial for the safety and efficacy of CD19 CAR-T following autologous hematopoietic stem cell transplantation (ASCT) for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) with High-Risk Prognostic Factors
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for advanced breast cancer: trial tests Two-Drug combo
Disease control Recruiting nowThe purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unre…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Balloon in the womb could save babies with rare birth defect
Disease control OngoingThe purpose of the study is to determine the infant survival and long-term effects of performing Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery and removal of the BALT Goldbal2 balloon at Children's Mercy Hospital. We hypothesize that FETO balloon placement may increase…
Phase: NA • Sponsor: Inna Lobeck • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New CAR t-cell combo aims to beat leukemia relapse
Disease control Recruiting nowThis is a multi-center, open-label, non-randomized, two-arm, non-inferior trial. Patients with r/r B-ALL would be assigned to the CD19 CAR and CD22 CAR T-cell sequential infusion group (Sequential CAR, Arm-1) and the CD19 CAR T-cell infusion bridging to hematopoietic stem cell tr…
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo pill aims to cut heart deaths in patients with failing kidneys
Disease control Recruiting nowThis is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/da…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for lung cancer: drug duo takes on standard therapy
Disease control Recruiting nowThe purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could an mRNA vaccine stop kidney cancer from returning?
Disease control OngoingThe primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that intism…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Brain tumor trial aims to boost radiation without boosting harm
Disease control Recruiting nowGlioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted, but causes more toxicity. To address this, the multic…
Phase: PHASE2 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Smart immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThe goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors tha…
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC